These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18566974)

  • 41. Decreased in vivo α2 adrenoceptor binding in the Flinders Sensitive Line rat model of depression.
    Landau AM; Phan JA; Iversen P; Lillethorup TP; Simonsen M; Wegener G; Jakobsen S; Doudet DJ
    Neuropharmacology; 2015 Apr; 91():97-102. PubMed ID: 25576372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635.
    Bailer UF; Frank GK; Henry SE; Price JC; Meltzer CC; Weissfeld L; Mathis CA; Drevets WC; Wagner A; Hoge J; Ziolko SK; McConaha CW; Kaye WH
    Arch Gen Psychiatry; 2005 Sep; 62(9):1032-41. PubMed ID: 16143735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans.
    Kegeles LS; Martinez D; Kochan LD; Hwang DR; Huang Y; Mawlawi O; Suckow RF; Van Heertum RL; Laruelle M
    Synapse; 2002 Jan; 43(1):19-29. PubMed ID: 11746730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region.
    Hirvonen J; Kajander J; Allonen T; Oikonen V; Någren K; Hietala J
    J Cereb Blood Flow Metab; 2007 Jan; 27(1):185-95. PubMed ID: 16685258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.
    Zhu Z; Guo N; Narendran R; Erritzoe D; Ekelund J; Hwang DR; Bae SA; Laruelle M; Huang Y
    Nucl Med Biol; 2004 Nov; 31(8):983-94. PubMed ID: 15607480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET.
    Schou M; Pike VW; Sóvágó J; Gulyás B; Gallagher PT; Dobson DR; Walter MW; Rudyk H; Farde L; Halldin C
    Bioorg Med Chem; 2007 Jan; 15(2):616-25. PubMed ID: 17123820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat.
    O'Neill M; Brown VJ
    Psychopharmacology (Berl); 2006 Jan; 184(1):46-55. PubMed ID: 16344986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors.
    Kessler RM; Votaw JR; de Paulis T; Bingham DR; Ansari MS; Mason NS; Holburn G; Schmidt DE; Votaw DB; Manning RG
    Synapse; 1993 Nov; 15(3):169-76. PubMed ID: 8278895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of reduction in endogenous dopamine on extrastriatal binding of [11C]FLB 457 in rat brain--an ex vivo study.
    Ahmad R; Hirani E; Grasby PM; Hume SP
    Synapse; 2006 Mar; 59(3):162-72. PubMed ID: 16358331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
    Pinna A
    CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Istradefylline: first global approval.
    Dungo R; Deeks ED
    Drugs; 2013 Jun; 73(8):875-82. PubMed ID: 23700273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Occupancy of adenosine A
    Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
    Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How do adenosine A
    Mori A
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S13-S20. PubMed ID: 33349575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitation of the A
    Gündel D; Toussaint M; Lai TH; Deuther-Conrad W; Cumming P; Schröder S; Teodoro R; Moldovan RP; Pan-Montojo F; Sattler B; Kopka K; Sabri O; Brust P
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allosteric Interactions between Adenosine A
    Prasad K; de Vries EFJ; Elsinga PH; Dierckx RAJO; van Waarde A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adenosine A
    Wydra K; Gawliński D; Gawlińska K; Frankowska M; Borroto-Escuela DO; Fuxe K; Filip M
    Cells; 2020 Jun; 9(6):. PubMed ID: 32492952
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Vuorimaa A; Rissanen E; Airas L
    Contrast Media Mol Imaging; 2017; 2017():6975841. PubMed ID: 29348737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo evaluation of [
    Zhou X; Khanapur S; de Jong JR; Willemsen AT; Dierckx RA; Elsinga PH; de Vries EF
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):577-589. PubMed ID: 26917190
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.